10 Unusual Stocks Attracting Huge Interest In The Pre-Market Right Now


Here’s where we see the heat today:

Adobe bought by Microsoft? Genzyme hunts for a new acquirer, Kulicke is dropping like a rock on bad revenue guidance, and more…

PHARMA CATALYST: Onyx (ONXX) gets request for more data on a cancer treatment, stock tanking

REVENUE DIVE: Kulicke & Soffa (KLIC) dropping hard after saying Q1 2011 revenue will be lower than Q4

M&A: Johnson & Johnson has said they will buy Crucell (CRXL), still massive volume in the shares

Probably the M&A arbitrage players. Read about the deal here.

PHARMA CATALYST: Avanir (AVNR) has a major FDA decision coming on October 29th

Shares are already seeing action. Read about the FDA decision here.

DOWNGRADE: F5 Networks (FFIV) dropping after its price target was cut by Goldman.

Worth a look.

JOINING THE S&P SMALL CAP INDEX: Atlantic Telenetwork (ATNI) popping after S&P says ATNI will join their small cap index

ODD: Atlas Energy (ATLS) tanking

Is it because law firms are targeting companies such as itself? Read about it here.

CAPITAL STRUCTURE: Cytori Therapeutics (CYTX) tanking after pricing its public offering at just $4.50 per share

M&A: Genzyme (GENZ) is looking for other potential acquirers

TENDER OFFER: Offer for Rescare (RSCR) shares begins, at $13.25 per share

EARNINGS: Seagate (STX) reports, jumping

PHARMA CATALYST: Onyx (ONXX) gets request for more data on a cancer treatment, stock tanking

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.